Fisetin for a longer life: what the research shows so far

Fisetin is a plant compound found in strawberries, among other foods. Researchers are studying it as a possible agent against cellular aging processes. Can it also help people live longer in good health? So far there is no solid evidence for that. The strongest results come from animal studies. What they might mean for humans depends on, among other things, how fisetin acts on cells, how much of it actually reaches the body’s tissues and how possible changes can be measured at all.

What fisetin does at the cellular level

Fisetin belongs to the flavonoids, a group of plant polyphenols. Preclinical studies have described a senolytic effect: senolytics are substances that can selectively trigger the death of senescent cells. These cells no longer divide, yet they resist the normal programmed cell death known as apoptosis. They accumulate with age, and as they do, they release pro-inflammatory molecules, growth factors and protein-degrading enzymes.

This secretion pattern is called the senescence-associated secretory phenotype, or SASP for short. It can promote chronic low-grade inflammation and tissue dysfunction and speed up several characteristic aging processes. The scientific background is explained in a review on cellular senescence and senolytics.

One proposed explanation for fisetin’s effect involves the BCL-2 protein family. These proteins regulate the intrinsic, mitochondria-mediated pathway of apoptosis. Senescent cells make more anti-apoptotic proteins such as BCL-2, BCL-XL and BCL-W to avoid being cleared. These proteins stop cytochrome c from being released from the mitochondria. As a result, caspases, the enzymes that carry out cell death, stay inactive.

Fisetin is thought to disrupt this protective mechanism and so allow senescent cells to undergo apoptosis. Healthy, dividing cells are supposed to remain largely unaffected. This selectivity is not absolute, however. Senescent cells may have a lower threshold for triggering apoptosis because they depend more heavily on these survival pathways.

Fisetin has also been described as acting on other signaling pathways relevant to cellular aging:

It activates sirtuins, especially SIRT1. These proteins influence DNA repair, mitochondrial function and metabolic regulation.
Through the NRF2 pathway, fisetin can increase the production of antioxidant enzymes and so reduce oxidative stress.
In animal models, it improves measures of mitochondrial health and lowers markers of systemic inflammation, meaning inflammation that affects the whole organism.

Mechanistically, these processes are distinct from the senolytic effect. They could still influence healthspan, the part of life spent in good health. More background is available in the general review “New Perspectives for Fisetin”. The mechanisms described do not establish proven efficacy or safety in humans.

How fisetin relates to the hallmarks of aging

Fisetin interests longevity researchers mainly because it can reduce the burden of senescent cells in preclinical models. Cellular senescence is one of the established hallmarks of aging. The buildup of these cells can itself drive aging processes: senescent cells release pro-inflammatory messengers such as IL-6 and IL-8. They also release matrix metalloproteinases, which break down structures outside the cells, and growth factors that promote fibrosis, an excessive buildup of connective tissue. By clearing senescent cells, fisetin could weaken this chain of effects.

This also connects it to chronic age-associated inflammation, often called inflammaging. The SASP of senescent cells is a major contributor to a baseline level of inflammation that rises with age. In animal models, circulating inflammatory markers fall when senolytic interventions reduce the number of senescent cells. That may have downstream effects on various age-related disease processes, including cardiovascular disease, neurodegenerative changes and metabolic disorders.

The described effects on mitochondria touch on another hallmark of aging: mitochondrial dysfunction. Senescent cells often show impaired mitochondrial respiration and produce more reactive oxygen species, which can damage cell components. By clearing such cells and supporting the formation of new mitochondria through SIRT1, fisetin could help preserve cellular energy production.

Effects on the nutrient-sensing pathways mTOR and AMPK have also been described. Among other things, these pathways regulate cell growth, metabolic adaptation and autophagy, the cell’s own process for breaking down and recycling its components.

Why senescent cells accumulate and where fisetin comes in

Various processes can trigger a cell’s senescence program: DNA damage from oxidative stress, shortening of the telomeres at the ends of chromosomes, activation of growth-promoting oncogenes and mitochondrial dysfunction. The body can remove such cells through immune surveillance, mainly with the help of natural killer cells and macrophages. With age, though, immune function declines. When senescent cells are removed more slowly than new ones form, they accumulate and can speed up tissue aging.

Fisetin’s described senolytic effect targets cells that are already senescent by lowering the threshold for their programmed cell death. This mechanism neither prevents cells from becoming senescent nor returns them to their previous state. The aim is to remove existing senescent cells that already contribute to tissue dysfunction. Senostatic agents work differently: they suppress the SASP without killing the cells. Still other interventions aim to prevent or reduce the onset of senescence.

How effective fisetin is as a senolytic depends on the cell type and on what triggered the senescence:

In vitro studies, meaning studies outside a living organism, show a stronger effect on senescent human umbilical vein endothelial cells than on senescent fibroblasts. Endothelial cells line the blood vessels; fibroblasts are responsible, among other things, for building connective tissue.
These differences reflect the fact that cell types produce different amounts of BCL-2 family proteins and rely on different additional survival pathways.
In animal models, fisetin reduces senescence markers in fat tissue, the kidneys and the heart. The strength of the effect varies between tissues, however.
A single senolytic may therefore not clear senescent cells equally well in all tissues. Combinations could be a subject for further research.

The described effects on senescence and lifespan include the preclinical paper “Fisetin is a senotherapeutic that extends health and lifespan”.

Which dietary and environmental factors affect the senescent cell burden

A chronic calorie surplus has been linked to faster accumulation of senescent cells through metabolic stress and insulin resistance, particularly with a diet high in refined carbohydrates and saturated fats. Conversely, calorie restriction and time-restricted eating reduce the senescent cell burden in animal models. Increased autophagy and improved mitochondrial function probably contribute.

Lack of exercise also favors unfavorable conditions. Exercise activates signaling pathways that can support the clearance of senescent cells, and it reduces systemic inflammation.

UV radiation, air pollution and heavy metals increase DNA damage and oxidative stress; both can trigger cellular senescence. Smoking promotes the buildup of senescent cells in lung tissue especially strongly. Chronic psychological stress can raise cortisol levels. This has been linked to faster epigenetic aging and higher senescence markers in some tissues.

Why the same senolytic might work differently in different people

How people respond to fisetin could depend on genetic differences, their starting burden of senescent cells and their individual metabolic profile. Variants in genes that encode BCL-2 family proteins can affect how readily senescent cells enter apoptosis in response to senolytics. This leads to the hypothesis that people with higher baseline activity of anti-apoptotic proteins might need higher doses or combination therapies to achieve meaningful cell clearance. It is not an established basis for individual dosing in humans.

Even among people of the same chronological age, the senescent cell burden can vary considerably. Lifetime exposure to stressors, immune function and the capacity of the body’s own clearance mechanisms all play a role. With a high starting burden, a senolytic intervention could conceivably have stronger effects; with a low burden, the change might be small. Epigenetic clocks and senescence-associated biomarkers such as p16INK4a could give clues about the starting point. They are not yet standard clinical tools for this purpose, however.

Metabolic health could also influence the response:

Insulin resistance and chronic inflammation create a tissue environment that can favor the survival of senescent cells and amplify the SASP.
People with metabolic syndrome could have a higher share of senescent cells in fat tissue and the liver. These cells could also be harder to clear.
With better metabolic health, fewer senescent cells might be present and immune-mediated clearance might work more efficiently. The added benefit of senolytics taken from outside could therefore be smaller.

These ideas about genetic and metabolic differences are mechanistic explanations, not clinically proven predictions of how fisetin works.

The gut microbiome and the metabolism of senolytic substances

The gut microbiome affects the metabolism and bioavailability of flavonoids, the group fisetin belongs to. Certain bacterial species can cleave glycosidic bonds and alter the structure of flavonoids. This can change how well they are absorbed and how much becomes available in the body.

With an altered or imbalanced microbiome, fisetin could be metabolized differently. That could lead to different concentrations in blood plasma and a different distribution in tissues. This field of research is still at an early stage. Microbiome composition therefore offers a possible explanation for differences between people; so far it cannot reliably predict senolytic efficacy.

What the research actually supports, and where the evidence thins out

The strongest evidence for fisetin’s senolytic effects comes from animal studies. In old mice, intermittent treatment, meaning treatment given at intervals, extended both median and maximum lifespan. Median lifespan is the point at which half of a study group is still alive; maximum lifespan captures the longest observed lifetimes. The researchers also reported fewer senescence markers in several tissues and better physical function. This includes the 2018 study by Yousefzadeh and colleagues.

The doses used in these experiments are far above amounts that can be reached through food alone. A simple conversion based on body weight, however, does not give a validated dose for humans. The figures for strawberries are also contradictory and therefore unsuitable for a practical comparison.

Clinical studies in humans have so far been limited in both number and size. A pilot study described in women with obesity reportedly provided indications of feasibility and some reduction in inflammatory markers. The details of this study, however, cannot be clearly matched to the bibliography, and the safety assessment is unconfirmed as well. The study was not designed to assess life extension.

Other studies look at fisetin in osteoarthritis, chronic kidney disease and frailty. The results described so far are preliminary. A central difficulty is that the senescent cell burden in humans is hard to measure without invasive procedures. Surrogate markers such as pro-inflammatory cytokines in the blood are influenced by many other factors.

Bioavailability further limits possible use. Fisetin taken by mouth is poorly absorbed and quickly metabolized, so only low concentrations are reached in blood plasma. New formulations using liposomal encapsulation or nanoparticle carrier systems are meant to solve this problem.

When interpreting the results, senolytic and senostatic effects must be kept apart. Some benefits in animal models could stem from antioxidant and anti-inflammatory properties rather than from directly clearing senescent cells. To tell the mechanisms apart in humans, studies would need to measure senescence markers directly in tissue samples before and after treatment. Such biopsies are invasive and are rarely done for this purpose outside research.

Which measurements say something meaningful about the senescent cell burden

Anyone who wants to track the accumulation of senescent cells and possible effects of senolytic interventions needs measures that reflect cellular aging processes. Chronological age alone is not enough. Epigenetic methods such as GrimAge and DunedinPACE use DNA methylation patterns, chemical tags on DNA, to estimate aspects of biological aging. They have been linked to the senescent cell burden but do not measure senescence directly. Repeated measurements can provide information on age-related changes over time.

Inflammatory markers capture a different aspect:

High-sensitivity C-reactive protein (hsCRP), along with IL-6 and TNF-alpha, can be elevated when inflammatory activity and the senescent cell burden are high.
These markers are not specific to senescence. A persistent mild elevation without an acute infection or injury can fit a picture of age-associated inflammation, but it does not prove it.
Together with metabolic and risk markers such as fasting insulin, HbA1c and ApoB, they allow a broader look at how metabolic health and cardiovascular risk relate to aging processes. HbA1c describes longer-term blood sugar exposure; ApoB helps estimate the number of lipoprotein particles that can potentially damage blood vessels.

Body composition can also add information. Senescent cells can accumulate in fat tissue, particularly in the visceral fat around the internal organs. DEXA scans measure body fat and lean mass and, depending on the method, can estimate visceral fat. Changes over time are therefore discussed as possible indirect clues to the senescent cell burden.

Grip strength and VO₂max, the maximum oxygen uptake during exercise, are functional measures. They have been linked to biological age and, in animal models, to the senescent cell burden. They are not themselves suitable as senescence biomarkers, but they can reflect the physical consequences of aging processes and physical capacity.

Baseline measurements before supplementation and repeat measurements after several months could document changes. On their own, however, such changes prove neither that fisetin cleared senescent cells nor that it caused the changes.

How insights from longevity research can help establish a baseline

Taking a longer-term view of metabolism, inflammatory activity and, where relevant, hormonal relationships can help put health trends in context. Repeated measurements of hsCRP, insulin, ApoB, homocysteine and IGF-1 can, depending on the medical context, provide information on metabolism, inflammation and age-related risks. IGF-1 is an insulin-like growth factor. Homocysteine is a metabolic intermediate whose concentration is influenced by various factors.

Which of these values make sense depends on the specific question. No universal priority list can be drawn from them. And even when values change after shifts in diet, more exercise or targeted supplementation, that does not automatically prove a shift in biological age.

For a longer healthy life, it therefore makes more sense to build an overall picture of your health over time than to focus on a single compound or a single intake protocol. Data like these can help you make well-founded decisions about health priorities.

Frequently asked questions

What is fisetin and how does it act as a senolytic?

Fisetin is a plant flavonoid with senolytic activity described in preclinical studies. Under certain experimental conditions, it can preferentially trigger the death of senescent cells. One described mechanism is the disruption of anti-apoptotic proteins of the BCL-2 family. Senescent cells make more of these proteins to avoid being cleared. When these survival mechanisms are disrupted, the cells can enter apoptosis. Healthy, dividing cells are supposed to remain largely unaffected. This selectivity is not absolute.

Separately, activation of sirtuins, a reduction in oxidative stress through the NRF2 pathway and effects on mitochondrial health have been described. These effects are not the same as a proven benefit for human lifespan.

Which foods contain fisetin, and in what amounts?

Fisetin occurs in strawberries, apples, persimmons, onions and cucumbers. Strawberries are named as the food with the highest concentration; the other foods contain markedly lower concentrations. The specific figures for strawberries contradict each other, however, and must be checked before any practical use.

The amounts used in the animal experiments described cannot simply be matched by normal consumption of foods that contain fisetin. And scaling up the animal dose does not yield an intake recommendation for humans.

How does fisetin differ from other senolytic approaches?

The senolytic effect of fisetin under study aims to remove existing senescent cells by lowering their threshold for apoptosis. Senostatic approaches work differently. Rapamycin’s described effect, for example, is meant to suppress SASP secretion without killing the senescent cells. Interventions such as calorie restriction, by contrast, act among other things on the rate at which new senescent cells form.

The combination of dasatinib and quercetin is also being studied for clearing senescent cells, but it partly uses different pathways. Quercetin alone is described as a weaker senolytic than fisetin. Together with dasatinib it could act synergistically, meaning the two substances could complement each other. Such comparisons depend on cell type and experimental conditions and do not justify combining them on your own.

What do the animal studies on fisetin actually show?

In old mice given intermittent fisetin treatment, researchers described an extension of median and maximum lifespan, fewer senescence markers in fat tissue, kidneys and heart, and improved physical function. A typical dose given is 100 mg/kg of body weight, administered at intervals. A key bibliographic source is the paper by Yousefzadeh and colleagues.

The effect varies by tissue and cell type. In vitro studies, for example, show stronger clearance of senescent endothelial cells than of senescent fibroblasts. Differences in the production of BCL-2 family proteins are among the explanations offered. In animal models, intermittent dosing has also been described as improving arterial function, including in the study “Intermittent supplementation with fisetin improves arterial function in old mice by decreasing cellular senescence”. These findings cannot be transferred directly to humans.

What do clinical studies of fisetin in humans show?

Human studies have so far been limited in number and size. A pilot study described in women with obesity reportedly provided indications of safety and feasibility as well as some reduction in inflammatory markers. Life extension was not studied. A matching entry in the bibliography for the exact description is missing, however, so the safety assessment is not confirmed either.

Other studies look at osteoarthritis, chronic kidney disease and frailty. The human studies described mainly provide data on safety and feasibility. Proof of a longer lifespan or healthspan is missing. The papers drawn on here do not include results from sufficiently large, statistically meaningful longevity studies.

Why is fisetin’s bioavailability a problem for use in life extension?

Fisetin taken by mouth is poorly absorbed and is quickly broken down during what is called first-pass metabolism, before larger amounts reach the systemic circulation. As a result, usual doses produce only low concentrations in blood plasma. On top of that comes the large gap in quantity between fisetin from food and the doses used in research protocols.

Liposomal encapsulation and nanoparticle carrier systems are being developed to improve bioavailability. The gut microbiome also affects flavonoid metabolism and could contribute to different amounts becoming available in the body from person to person at the same dose.

How does fisetin relate to the hallmarks of aging?

The senolytic effect is aimed directly at cellular senescence, one of the central hallmarks of aging. When the number of senescent cells falls, the chronic inflammation triggered by their SASP can also decline. This inflammaging in turn affects several other aging processes.

The described activation of SIRT1 links fisetin to epigenetic regulation and the formation of new mitochondria. Antioxidant effects through NRF2 can reduce oxidative stress, which in turn can trigger DNA damage and further senescence. Effects on mTOR and AMPK have also been described, meaning on pathways that regulate autophagy and the cell’s response to nutrient supply. These mechanistic connections explain the research interest, but they do not prove life extension in humans.

Which biomarkers could show whether a fisetin protocol is working?

None of the routine values mentioned here can, on its own, prove that fisetin clears senescent cells. Outside of tissue testing, there is no single biomarker that measures this clearance directly.

Practical indirect measures under discussion include hsCRP, IL-6 and TNF-alpha for inflammatory activity, and fasting insulin and HbA1c for metabolic dysfunction. ApoB and homocysteine capture aspects of cardiovascular risk that chronic inflammation can help shape. Epigenetic methods such as GrimAge and DunedinPACE can track different aspects of biological aging over time.

DEXA measurements of body composition, especially changes in visceral fat, have also been proposed as indirect clues. The idea behind this is that fat tissue can be an important site where senescent cells accumulate. An improvement in these values, however, is not specific proof of a senolytic effect. It confirms neither the efficacy of a fisetin protocol nor an extension of healthspan.

References

Grynkiewicz G, Demchuk OM (2019). New Perspectives for Fisetin. Frontiers in chemistry, 7, 697. https://doi.org/10.3389/fchem.2019.00697. PubMed
Yousefzadeh MJ, Zhu Y, McGowan SJ, Angelini L, Fuhrmann-Stroissnigg H, Xu M, Ling YY, Melos KI, Pirtskhalava T, Inman CL, McGuckian C, Wade EA, Kato JI, Grassi D, Wentworth M, Burd CE, Arriaga EA, Ladiges WL, Tchkonia T, … Niedernhofer LJ (2018). Fisetin is a senotherapeutic that extends health and lifespan. EBioMedicine, 36, 18-28. https://doi.org/10.1016/j.ebiom.2018.09.015. PubMed
Chaib S, Tchkonia T, Kirkland JL (2022). Cellular senescence and senolytics: the path to the clinic. Nature medicine, 28(8), 1556-1568. https://doi.org/10.1038/s41591-022-01923-y. PubMed
Mahoney SA, Venkatasubramanian R, Darrah MA, Ludwig KR, VanDongen NS, Greenberg NT, Longtine AG, Hutton DA, Brunt VE, Campisi J, Melov S, Seals DR, Rossman MJ, Clayton ZS (2024). Intermittent supplementation with fisetin improves arterial function in old mice by decreasing cellular senescence. Aging cell, 23(3), e14060. https://doi.org/10.1111/acel.14060. PubMed
Lee E, Burns M (2024). The Effects of Fisetin on Reducing Biological Aging: A Pilot Study. Alternative therapies in health and medicine, 30(9), 6-10. https://pubmed.ncbi.nlm.nih.gov/39269340/

Supplementary biomarker information from the original provider; not scientific evidence of efficacy for fisetin: